title: Accuracy of a clinical PET/CT vs. a preclinical μPET system for monitoring treatment effects in tumour xenografts.
abstract: OBJECTIVE
  Small animal imaging is of growing importance for preclinical research and drug development. Tumour xenografts implanted in mice can be visualized with a clinical PET/CT (cPET); however, it is unclear whether early treatment effects can be monitored. Thus, we investigated the accuracy of a cPET versus a preclinical μPET using (18)F-FDG for assessing early treatment effects.
  
  
  METHODS
  The spatial resolution and the quantitative accuracy of a clinical and preclinical PET were evaluated in phantom experiments. To investigate the sensitivity for assessing treatment response, A431 tumour xenografts were implanted in nude mice. Glucose metabolism was measured in untreated controls and in two therapy groups (either one or four days of antiangiogenic treatment). Data was validated by γ-counting of explanted tissues.
  
  
  RESULTS
  In phantom experiments, cPET enabled reliable separation of boreholes≥5mm whereas μPET visualized boreholes≥2mm. In animal studies, μPET provided significantly higher tumour-to-muscle ratios for untreated control tumours than cPET (3.41±0.87 vs. 1.60±.0.28, respectively; p<0.01). During treatment, cPET detected significant therapy effects at day 4 (p<0.05) whereas μPET revealed highly significant therapy effects even at day one (p<0.01). Correspondingly, γ-counting of explanted tumours indicated significant therapy effects at day one and highly significant treatment response at day 4. Correlation with γ-counting was good for cPET (r=0.74; p<0.01) and excellent for μPET (r=0.85; p<0.01).
  
  
  CONCLUSIONS
  Clinical PET is suited to investigate tumour xenografts≥5mm at an advanced time-point of treatment. For imaging smaller tumours or for the sensitive assessment of very early therapy effects, μPET should be preferred.
authors: Department of Experimental Molecular Imaging, RWTH-Aachen University, Aachen, Germany.
authors: Karin
authors: K
authors: Palmowski
authors: Oliver
authors: O
authors: Winz
authors: Anne
authors: A
authors: Rix
authors: Jessica
authors: J
authors: Bzyl
authors: Florian F
authors: FF
authors: Behrendt
authors: Frederic A
authors: FA
authors: Verburg
authors: Felix M
authors: FM
authors: Mottaghy
authors: Moritz
authors: M
authors: Palmowski
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D045744:Cell Line, Tumor; D016903:Drug Monitoring / Q000295:instrumentation / Q000662:veterinary*; D004867:Equipment Design; D019544:Equipment Failure Analysis; D005260:Female; D019788:Fluorodeoxyglucose F18; D007211:Indoles / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D064847:Multimodal Imaging / Q000295:instrumentation / Q000662:veterinary*; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000295:instrumentation / Q000662:veterinary*; D011758:Pyrroles / Q000627:therapeutic use*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed / Q000295:instrumentation / Q000662:veterinary*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000077210:Sunitinib